Allergan to acquire Vitae Pharma

Allergan, the maker of Botox, will Vitae Pharmaceuticals, a drugmaker focused on dermatology segment at $639 million (€567 million).
Vitae is developing an experimental drug for psoriasis, an autoimmune skin disease, and another medicine for atopic dermatitis, which causes itching and inflammation. The drugs are in mid-stage clinical testing.

This deal will help allergan to errich dermatology pipeline.